In numerous forms of cancerous disease, HER2-overexpressing tumors present a large proportion of diagnosed cases, notably in 15–20% of breast cancer [1], 22% of gastric tumors [2], and 4% of colorectal tumors [3], and HER2 overexpression is typically connected with poor prognosis. This evidence concerns the gene ERBB2 and colorectal neoplasm.